Tango Therapeutics Aims for Market Entry After Clinical Validation

Tango Therapeutics, based in Boston, is a biotechnology company specialized in developing new cancer therapies based on the concept of synthetic lethality. The company exploits genetic vulnerabilities of tumor cells to specifically halt their growth while leaving healthy cells unaffected. The pipeline focuses on drug candidates such as TNG462 and TNG456, targeting tumors with specific genetic alterations such as MTAP deletion and PRMT5 inhibition. TNG260, which targets cancers with STK11 mutations, is also in clinical testing. After a phase of strategic...